We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Amplify Junior Silver Miners ETF | AMEX:SILJ | AMEX | Exchange Traded Fund |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 11.42 | 0 | 00:00:00 |
|
The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete. |
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM NPORT-P Monthly Portfolio Investments Report |
| Confidential | ☐ |
| Filer CIK | 0001467831 |
| Filer CCC | ******** |
| Filer Investment Company Type | |
| Is this a LIVE or TEST Filing? | ☐ LIVE ☐ TEST |
| Would you like a Return Copy? | ☐ |
| Is this an electronic copy of an official filing submitted in paper format? | ☐ |
| Name | |
| Phone | |
| E-Mail Address |
| Notify via Filing Website only? | ☐ |
| Notification E-mail Address | |
| Series ID | S000068972 |
| Class (Contract) ID | C000220417 |
| a. Name of Registrant | ETF Managers Trust |
| b. Investment Company Act file number for Registrant: (e.g., 811-______) | 811-22310 |
| c. CIK number of Registrant | 0001467831 |
| d. LEI of Registrant | 549300K4RW5UJ3CZL626 |
| e. Address and telephone number of Registrant: |
| i. Street Address 1 | 30 Maple Street |
| ii. Street Address 2 | Suite 2 |
| iii. City | Summit |
| iv. State, if applicable | |
| v. Foreign country, if applicable | |
| vi. Zip / Postal Code | 07901 |
| vii. Telephone number | 908-897-0513 |
| a. Name of Series. | ETFMG Treatments Testing and Advancements ETF |
| b. EDGAR series identifier (if any). | S000068972 |
| c. LEI of Series. | 549300CHSUJZU20KSY26 |
| a. Date of fiscal year-end. | 2023-09-30 |
| b. Date as of which information is reported. | 2023-03-31 |
| a. Does the Fund anticipate that this will be its final filing on Form N PORT? | ☐ Yes ☒ No |
| Report the following information for the Fund and its consolidated subsidiaries. |
| a. Total assets, including assets attributable to miscellaneous securities reported in Part D. | 26103594.490000000000 |
| b. Total liabilities. | 7181163.660000000000 |
| c. Net assets. | 18922430.830000000000 |
| a. Assets attributable to miscellaneous securities reported in Part D. | 0.000000000000 |
| b. Assets invested in a Controlled Foreign Corporation for the purpose of investing in certain types of instruments such as, but not limited to, commodities. | 0.000000000000 |
| c. Borrowings attributable to amounts payable for notes payable, bonds, and similar debt, as reported pursuant to rule 6-04(13)(a) of Regulation S-X [17 CFR 210.6-04(13)(a)]. |
| Amounts payable within one year. | |
| Banks or other financial institutions for borrowings. | 0.000000000000 |
| Controlled companies. | 0.000000000000 |
| Other affiliates. | 0.000000000000 |
| Others. | 0.000000000000 |
| Amounts payable after one year. | |
| Banks or other financial institutions for borrowings. | 0.000000000000 |
| Controlled companies. | 0.000000000000 |
| Other affiliates. | 0.000000000000 |
| Others. | 0.000000000000 |
| d. Payables for investments purchased either (i) on a delayed delivery, when-issued, or other firm commitment basis, or (ii) on a standby commitment basis. |
| (i) On a delayed delivery, when-issued, or other firm commitment basis: | 0.000000000000 |
| (ii) On a standby commitment basis: | 0.000000000000 |
| e. Liquidation preference of outstanding preferred stock issued by the Fund. | 0.000000000000 |
| f. Cash and cash equivalents not reported in Parts C and D. |
| If the average value of the Fund's debt securities positions for the previous three months, in the aggregate, exceeds 25% or more of the Fund's net asset value, provide: |
| a. Interest Rate Risk (DV01). For each currency for which the Fund had a value of 1% or more of the Fund’s net asset value, provide the change in value of the portfolio resulting from a 1 basis point change in interest rates, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years. |
| b. Interest Rate Risk (DV100). For each currency for which the Fund had a value of 1% or more of the Fund’s net asset value, provide the change in value of the portfolio resulting from a 100 basis point change in interest rates, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years. |
| Currency Metric Record | ISO Currency code | 3 month | 1 year | 5 years | 10 years | 30 years | — | — | — | — | — | — | — |
|---|
| c. Credit Spread Risk (SDV01, CR01 or CS01). Provide the change in value of the portfolio resulting from a 1 basis point change in credit spreads where the shift is applied to the option adjusted spread, aggregated by investment grade and non-investment grade exposures, for each of the following maturities: 3 month, 1 year, 5 years, 10 years, and 30 years. |
| Credit Spread Risk | 3 month | 1 year | 5 years | 10 years | 30 years | — | — | — | — | — | — |
|---|
|
For purposes of Item B.3., calculate value as the sum of the absolute values of: (i) the value of each debt security, (ii) the notional value of each swap, including, but not limited to, total return swaps, interest rate swaps, and credit default swaps, for which the underlying reference asset or assets are debt securities or an interest rate; (iii) the notional value of each futures contract for which the underlying reference asset or assets are debt securities or an interest rate; and (iv) the delta-adjusted notional value of any option for which the underlying reference asset is an asset described in clause (i),(ii), or (iii). Report zero for maturities to which the Fund has no exposure. For exposures that fall between any of the listed maturities in (a) and (b), use linear interpolation to approximate exposure to each maturity listed above. For exposures outside of the range of maturities listed above, include those exposures in the nearest maturity. |
| a. For each borrower in any securities lending transaction, provide the following information: |
| Borrower Information Record | Name of borrower | LEI (if any) of borrower | Aggregate value of all securities on loan to the borrower |
|---|---|---|---|
| #1 | BOFA SECURITIES, INC | 549300HN4UKV1E2R3U73 | 832865.940000000000 |
| #2 | GOLDMAN, SACHS & CO | FOR8UP27PHTHYVLBNG30 | 1341639.600000000000 |
| #3 | BMO NESBITT BURNS, INC | M3LKFDNSJGJ7TMLH6Z15 | 122598.000000000000 |
| #4 | BMO CAPITAL MARKETS CORP | RUC0QBLBRPRCU4W1NE59 | 257890.000000000000 |
| #5 | RBC DOMINION SECURITIES, INC | 549300QJJX6CVVUXLE15 | 1164073.350000000000 |
| #6 | PERSHING, LLC | ZI8Q1A8EI8LQFJNM0D94 | 142148.910000000000 |
| #7 | JEFFERIES, LLC | 58PU97L1C0WSRCWADL48 | 157872.330000000000 |
| #8 | COWEN AND COMPANY, LLC | 549300WR155U7DVMIW58 | 64635.000000000000 |
| #9 | CITIGROUP GLOBAL MARKETS, INC | MBNUM2BPBDO7JBLYG310 | 821387.610000000000 |
| #10 | BARCLAYS CAPITAL, INC | AC28XWWI3WIBK2824319 | 946954.470000000000 |
| b. Did any securities lending counterparty provide any non-cash collateral? | ☐ Yes ☒ No |
| a. Monthly total returns of the Fund for each of the preceding three months. If the Fund is a Multiple Class Fund, report returns for each class. Such returns shall be calculated in accordance with the methodologies outlined in Item 26(b) (1) of Form N-1A, Instruction 13 to sub-Item 1 of Item 4 of Form N-2, or Item 26(b) (i) of Form N-3, as applicable. |
| Monthly Total Return Record | Monthly total returns of the Fund for each of the preceding three months | Class identification number(s) (if any) of the Class(es) for which returns are reported | ||
| Month 1 | Month 2 | Month 3 | ||
| #1 | 4.890000000000 | -10.030000000000 | -3.100000000000 | C000220417 |
| b. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to derivatives for each of the following categories: commodity contracts, credit contracts, equity contracts, foreign exchange contracts, interest rate contracts, and other contracts. Within each such asset category, further report the same information for each of the following types of derivatives instrument: forward, future, option, swaption, swap, warrant, and other. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers. |
| i. Asset category. |
| c. For each of the preceding three months, monthly net realized gain (loss) and net change in unrealized appreciation (or depreciation) attributable to investment other than derivatives. Report in U.S. dollars. Losses and depreciation shall be reported as negative numbers. |
| Month | Monthly net realized gain(loss) | Monthly net change in unrealized appreciation (or depreciation) |
|---|---|---|
| Month 1 | 375323.310000000000 | 817021.260000000000 |
| Month 2 | -357320.270000000000 | -2044879.430000000000 |
| Month 3 | -1580116.150000000000 | 967702.600000000000 |
| a. Provide the aggregate dollar amounts for sales and redemptions/repurchases of Fund shares during each of the preceding three months. If shares of the Fund are held in omnibus accounts, for purposes of calculating the Fund's sales, redemptions, and repurchases, use net sales or redemptions/repurchases from such omnibus accounts. The amounts to be reported under this Item should be after any front-end sales load has been deducted and before any deferred or contingent deferred sales load or charge has been deducted. Shares sold shall include shares sold by the Fund to a registered unit investment trust. For mergers and other acquisitions, include in the value of shares sold any transaction in which the Fund acquired the assets of another investment company or of a personal holding company in exchange for its own shares. For liquidations, include in the value of shares redeemed any transaction in which the Fund liquidated all or part of its assets. Exchanges are defined as the redemption or repurchase of shares of one Fund or series and the investment of all or part of the proceeds in shares of another Fund or series in the same family of investment companies. |
| Month | Total net asset value of shares sold (including exchanges but excluding reinvestment of dividends and distributions) | Total net asset value of shares sold in connection with reinvestments of dividends and distributions | Total net asset value of shares redeemed or repurchased, including exchanges |
|---|---|---|---|
| Month 1 | .000000000000 | .000000000000 | -2426375.000000000000 |
| Month 2 | .000000000000 | .000000000000 | .000000000000 |
| Month 3 | .000000000000 | .000000000000 | -1083920.000000000000 |
| a. If applicable, provide the Fund's current Highly Liquid Investment Minimum. |
—
|
| b. If applicable, provide the number of days that the Fund's holdings in Highly Liquid Investments fell below the Fund's Highly Liquid Investment Minimum during the reporting period. |
—
|
| c. Did the Fund's Highly Liquid Investment Minimum change during the reporting period? | ☐ Yes ☐ No ☐ N/A |
| For portfolio investments of open-end management investment companies, provide the percentage of the Fund's Highly Liquid Investments that it has pledged as margin or collateral in connection with derivatives transactions that are classified among the following categories as specified in rule 22e-4 [17 CFR 270.22e-4]: |
| (1) Moderately Liquid Investments |
| (2) Less Liquid Investments |
| (3) Illiquid Investments |
| For purposes of Item B.8, when computing the required percentage, the denominator should only include assets (and exclude liabilities) that are categorized by the Fund as Highly Liquid Investments. |
| Classification |
—
|
| If the Fund is excepted from the rule 18f-4 [17 CFR 270.18f-4] program requirement and limit on fund leverage risk under rule 18f-4(c)(4) [17 CFR 270.18f-4(c)(4)], provide the following information: |
| a. Derivatives exposure (as defined in rule 18f-4(a) [17 CFR 270.18f-4(a)]), reported as a percentage of the Fund’s net asset value. |
—
|
| b. Exposure from currency derivatives that hedge currency risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value. |
—
|
| c. Exposure from interest rate derivatives that hedge interest rate risks, as provided in rule 18f-4(c)(4)(i)(B) [17 CFR 270.18f-4(c)(4)(i)(B)], reported as a percentage of the Fund's net asset value. |
—
|
| d. The number of business days, if any, in excess of the five-business-day period described in rule 18f-4(c)(4)(ii) [17 CFR 270.18f-4(c)(4)(ii)], that the Fund’s derivatives exposure exceeded 10 percent of its net assets during the reporting period. |
—
|
| For Funds subject to the limit on fund leverage risk described in rule 18f-4(c)(2) [17 CFR 270.18f-4(c)(2)], provide the following information, as determined in accordance with the requirement under rule 18f-4(c)(2)(ii) to determine the fund’s compliance with the applicable VaR test at least once each business day: |
| a. Median daily VaR during the reporting period, reported as a percentage of the Fund's net asset value. |
—
|
| b. For Funds that were subject to the Relative VaR Test during the reporting period, provide: | |
| i. As applicable, the name of the Fund’s Designated Index, or a statement that the Fund's Designated Reference Portfolio is the Fund’s Securities Portfolio. |
—
|
| ii. As applicable, the index identifier for the Fund’s Designated Index. |
—
|
| iii. Median VaR Ratio during the reporting period, reported as a percentage of the VaRof the Fund's Designated Reference Portfolio. |
—
|
| c. Backtesting Results. Number of exceptions that the Fund identified as a result of its backtesting of its VaR calculation model (as described in rule 18f-4(c)(1)(iv) [17 CFR 270.18f-4(c)(1)(iv)] during the reporting period. |
—
|
| For each investment held by the Fund and its consolidated subsidiaries, disclose the information requested in Part C. A Fund may report information for securities in an aggregate amount not exceeding five percent of its total assets as miscellaneous securities in Part D in lieu of reporting those securities in Part C, provided that the securities so listed are not restricted, have been held for not more than one year prior to the end of the reporting period covered by this report, and have not been previously reported by name to the shareholders of the Fund or to any exchange, or set forth in any registration statement, application, or report to shareholders or otherwise made available to the public. |
| Schedule of Portfolio Investments Record: 1 |
| a. Name of issuer (if any). | Abbott Laboratories |
| b. LEI (if any) of issuer. (1) | HQD377W2YR662HK5JX27 |
| c. Title of the issue or description of the investment. | Abbott Laboratories |
| d. CUSIP (if any). | 002824100 |
| At least one of the following other identifiers: |
| - ISIN | US0028241000 |
| - Ticker (if ISIN is not available). | ABT |
| Balance. (2) |
| a. Balance | 1345.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 136194.700000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7197526640 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 2 |
| a. Name of issuer (if any). | AbbVie Inc |
| b. LEI (if any) of issuer. (1) | FR5LCKFTG8054YNNRU85 |
| c. Title of the issue or description of the investment. | AbbVie Inc |
| d. CUSIP (if any). | 00287Y109 |
| At least one of the following other identifiers: |
| - ISIN | US00287Y1091 |
| - Ticker (if ISIN is not available). | ABBV |
| Balance. (2) |
| a. Balance | 894.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 142476.780000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7529517813 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 3 |
| a. Name of issuer (if any). | AbCellera Biologics Inc |
| b. LEI (if any) of issuer. (1) | 9845000861BC95FF9F73 |
| c. Title of the issue or description of the investment. | AbCellera Biologics Inc |
| d. CUSIP (if any). | 00288U106 |
| At least one of the following other identifiers: |
| - ISIN | CA00288U1066 |
| - Ticker (if ISIN is not available). | ABCL |
| Balance. (2) |
| a. Balance | 94496.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 712499.840000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 3.7653716185 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
CANADA (FEDERAL LEVEL)
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 691123.940000000000 |
| Schedule of Portfolio Investments Record: 4 |
| a. Name of issuer (if any). | Invivyd Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Invivyd Inc |
| d. CUSIP (if any). | 00534A102 |
| At least one of the following other identifiers: |
| - ISIN | US00534A1025 |
| - Ticker (if ISIN is not available). | IVVD |
| Balance. (2) |
| a. Balance | 35155.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 42186.000000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.2229417583 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 5 |
| a. Name of issuer (if any). | Adaptive Biotechnologies Corp |
| b. LEI (if any) of issuer. (1) | 549300ZTF7OT1FW66Q96 |
| c. Title of the issue or description of the investment. | Adaptive Biotechnologies Corp |
| d. CUSIP (if any). | 00650F109 |
| At least one of the following other identifiers: |
| - ISIN | US00650F1093 |
| - Ticker (if ISIN is not available). | ADPT |
| Balance. (2) |
| a. Balance | 44598.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 393800.340000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 2.0811297636 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 6 |
| a. Name of issuer (if any). | Alnylam Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | 529900S3ZI14OWRJII50 |
| c. Title of the issue or description of the investment. | Alnylam Pharmaceuticals Inc |
| d. CUSIP (if any). | 02043Q107 |
| At least one of the following other identifiers: |
| - ISIN | US02043Q1076 |
| - Ticker (if ISIN is not available). | ALNY |
| Balance. (2) |
| a. Balance | 5963.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 1194508.160000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 6.3126570298 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 7 |
| a. Name of issuer (if any). | Altimmune Inc |
| b. LEI (if any) of issuer. (1) | 549300EOYCQ8SW3NVE64 |
| c. Title of the issue or description of the investment. | Altimmune Inc |
| d. CUSIP (if any). | 02155H200 |
| At least one of the following other identifiers: |
| - ISIN | US02155H2004 |
| - Ticker (if ISIN is not available). | ALT |
| Balance. (2) |
| a. Balance | 16361.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 69043.420000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.3648760596 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 8 |
| a. Name of issuer (if any). | AN2 Therapeutics Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | AN2 Therapeutics Inc |
| d. CUSIP (if any). | 037326105 |
| At least one of the following other identifiers: |
| - ISIN | US0373261058 |
| - Ticker (if ISIN is not available). | ANTX |
| Balance. (2) |
| a. Balance | 6742.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 66543.540000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.3516648606 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 39480.000000000000 |
| Schedule of Portfolio Investments Record: 9 |
| a. Name of issuer (if any). | Arbutus Biopharma Corp |
| b. LEI (if any) of issuer. (1) | 25490064CESONAUIAS23 |
| c. Title of the issue or description of the investment. | Arbutus Biopharma Corp |
| d. CUSIP (if any). | 03879J100 |
| At least one of the following other identifiers: |
| - ISIN | CA03879J1003 |
| - Ticker (if ISIN is not available). | ABUS |
| Balance. (2) |
| a. Balance | 51963.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 157447.890000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.8320701046 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 10 |
| a. Name of issuer (if any). | Arcturus Therapeutics Holdings |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Arcturus Therapeutics Holdings Inc |
| d. CUSIP (if any). | 03969T109 |
| At least one of the following other identifiers: |
| - ISIN | US03969T1097 |
| - Ticker (if ISIN is not available). | ARCT |
| Balance. (2) |
| a. Balance | 8890.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 213093.300000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.1261412549 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 11 |
| a. Name of issuer (if any). | Assembly Biosciences Inc |
| b. LEI (if any) of issuer. (1) | 5299007Y1X8RBDFT8C40 |
| c. Title of the issue or description of the investment. | Assembly Biosciences Inc |
| d. CUSIP (if any). | 045396108 |
| At least one of the following other identifiers: |
| - ISIN | US0453961080 |
| - Ticker (if ISIN is not available). | ASMB |
| Balance. (2) |
| a. Balance | 16315.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 13711.130000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.0724596651 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 12 |
| a. Name of issuer (if any). | AstraZeneca PLC |
| b. LEI (if any) of issuer. (1) | PY6ZZQWO2IZFZC3IOL08 |
| c. Title of the issue or description of the investment. | AstraZeneca PLC |
| d. CUSIP (if any). | 046353108 |
| At least one of the following other identifiers: |
| - ISIN | US0463531089 |
| - Ticker (if ISIN is not available). | AZN |
| Balance. (2) |
| a. Balance | 2120.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 147149.200000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7776442748 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 13 |
| a. Name of issuer (if any). | Atea Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Atea Pharmaceuticals Inc |
| d. CUSIP (if any). | 04683R106 |
| At least one of the following other identifiers: |
| - ISIN | US04683R1068 |
| - Ticker (if ISIN is not available). | AVIR |
| Balance. (2) |
| a. Balance | 26460.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 88641.000000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.4684440429 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 14 |
| a. Name of issuer (if any). | Atossa Therapeutics Inc |
| b. LEI (if any) of issuer. (1) | 549300QRKP1JTNHD2366 |
| c. Title of the issue or description of the investment. | Atossa Therapeutics Inc |
| d. CUSIP (if any). | 04962H506 |
| At least one of the following other identifiers: |
| - ISIN | US04962H5063 |
| - Ticker (if ISIN is not available). | ATOS |
| Balance. (2) |
| a. Balance | 42442.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 30766.210000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.1625912140 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 15 |
| a. Name of issuer (if any). | Bio-Rad Laboratories Inc |
| b. LEI (if any) of issuer. (1) | 549300ZC1GPV35XYDK53 |
| c. Title of the issue or description of the investment. | Bio-Rad Laboratories Inc |
| d. CUSIP (if any). | 090572207 |
| At least one of the following other identifiers: |
| - ISIN | US0905722072 |
| - Ticker (if ISIN is not available). | BIO |
| Balance. (2) |
| a. Balance | 1537.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 736253.740000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 3.8909046444 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 16 |
| a. Name of issuer (if any). | BioCryst Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | 549300Z0INP1Z5NP6J59 |
| c. Title of the issue or description of the investment. | BioCryst Pharmaceuticals Inc |
| d. CUSIP (if any). | 09058V103 |
| At least one of the following other identifiers: |
| - ISIN | US09058V1035 |
| - Ticker (if ISIN is not available). | BCRX |
| Balance. (2) |
| a. Balance | 62568.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 521817.120000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 2.7576643016 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 122598.000000000000 |
| Schedule of Portfolio Investments Record: 17 |
| a. Name of issuer (if any). | BioNTech SE |
| b. LEI (if any) of issuer. (1) | 894500UZJ5LG1F8J1U58 |
| c. Title of the issue or description of the investment. | BioNTech SE |
| d. CUSIP (if any). | 09075V102 |
| At least one of the following other identifiers: |
| - ISIN | US09075V1026 |
| - Ticker (if ISIN is not available). | BNTX |
| Balance. (2) |
| a. Balance | 9060.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 1128604.200000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 5.9643721789 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
GERMANY
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 1094721.160000000000 |
| Schedule of Portfolio Investments Record: 18 |
| a. Name of issuer (if any). | Bristol-Myers Squibb Co |
| b. LEI (if any) of issuer. (1) | HLYYNH7UQUORYSJQCN42 |
| c. Title of the issue or description of the investment. | Bristol-Myers Squibb Co |
| d. CUSIP (if any). | 110122108 |
| At least one of the following other identifiers: |
| - ISIN | US1101221083 |
| - Ticker (if ISIN is not available). | BMY |
| Balance. (2) |
| a. Balance | 1995.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 138273.450000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7307383034 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 19 |
| a. Name of issuer (if any). | CEL-SCI Corp |
| b. LEI (if any) of issuer. (1) | 549300FIWOFSETIVMI17 |
| c. Title of the issue or description of the investment. | CEL-SCI Corp |
| d. CUSIP (if any). | 150837607 |
| At least one of the following other identifiers: |
| - ISIN | US1508376076 |
| - Ticker (if ISIN is not available). | CVM |
| Balance. (2) |
| a. Balance | 14522.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 33691.040000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.1780481604 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 17632.000000000000 |
| Schedule of Portfolio Investments Record: 20 |
| a. Name of issuer (if any). | Chimerix Inc |
| b. LEI (if any) of issuer. (1) | 5299002IR2GXUBEPKS66 |
| c. Title of the issue or description of the investment. | Chimerix Inc |
| d. CUSIP (if any). | 16934W106 |
| At least one of the following other identifiers: |
| - ISIN | US16934W1062 |
| - Ticker (if ISIN is not available). | CMRX |
| Balance. (2) |
| a. Balance | 29405.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 37050.300000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.1958009536 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 21 |
| a. Name of issuer (if any). | Co-Diagnostics Inc |
| b. LEI (if any) of issuer. (1) | 549300Z1JPESYWFM1R93 |
| c. Title of the issue or description of the investment. | Co-Diagnostics Inc |
| d. CUSIP (if any). | 189763105 |
| At least one of the following other identifiers: |
| - ISIN | US1897631057 |
| - Ticker (if ISIN is not available). | CODX |
| Balance. (2) |
| a. Balance | 9819.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 14532.120000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.0767983782 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 22 |
| a. Name of issuer (if any). | CorMedix Inc |
| b. LEI (if any) of issuer. (1) | 5299006YIA3L0MBW8358 |
| c. Title of the issue or description of the investment. | CorMedix Inc |
| d. CUSIP (if any). | 21900C308 |
| At least one of the following other identifiers: |
| - ISIN | US21900C3088 |
| - Ticker (if ISIN is not available). | CRMD |
| Balance. (2) |
| a. Balance | 13706.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 56742.840000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.2998707751 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 23 |
| a. Name of issuer (if any). | QuidelOrtho Corp |
| b. LEI (if any) of issuer. (1) | 549300YU8CMO9HF53113 |
| c. Title of the issue or description of the investment. | QuidelOrtho Corp |
| d. CUSIP (if any). | 219798105 |
| At least one of the following other identifiers: |
| - ISIN | US2197981051 |
| - Ticker (if ISIN is not available). | QDEL |
| Balance. (2) |
| a. Balance | 8759.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 780339.310000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 4.1238851235 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 24 |
| a. Name of issuer (if any). | Cue Biopharma Inc |
| b. LEI (if any) of issuer. (1) | 549300PBW78KZA33WC97 |
| c. Title of the issue or description of the investment. | Cue Biopharma Inc |
| d. CUSIP (if any). | 22978P106 |
| At least one of the following other identifiers: |
| - ISIN | US22978P1066 |
| - Ticker (if ISIN is not available). | CUE |
| Balance. (2) |
| a. Balance | 13528.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 48294.960000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.2552259825 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 25 |
| a. Name of issuer (if any). | Cue Health Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Cue Health Inc |
| d. CUSIP (if any). | 229790100 |
| At least one of the following other identifiers: |
| - ISIN | US2297901009 |
| - Ticker (if ISIN is not available). | HLTH |
| Balance. (2) |
| a. Balance | 49136.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 89427.520000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.4726005913 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 13613.600000000000 |
| Schedule of Portfolio Investments Record: 26 |
| a. Name of issuer (if any). | Dynavax Technologies Corp |
| b. LEI (if any) of issuer. (1) | 549300T5URIXWDILX594 |
| c. Title of the issue or description of the investment. | Dynavax Technologies Corp |
| d. CUSIP (if any). | 268158201 |
| At least one of the following other identifiers: |
| - ISIN | US2681582019 |
| - Ticker (if ISIN is not available). | DVAX |
| Balance. (2) |
| a. Balance | 42393.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 415875.330000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 2.1977901980 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 403397.010000000000 |
| Schedule of Portfolio Investments Record: 27 |
| a. Name of issuer (if any). | ETFMG Sit Ultra Short ETF |
| b. LEI (if any) of issuer. (1) | 549300GKNILOXP5WYO32 |
| c. Title of the issue or description of the investment. | ETFMG Sit Ultra Short ETF |
| d. CUSIP (if any). | 26924G789 |
| At least one of the following other identifiers: |
| - ISIN | US26924G7896 |
| - Ticker (if ISIN is not available). | VALT |
| Balance. (2) |
| a. Balance | 1235805.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 2421610.000000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 12.7975629651 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Registered fund
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the investment representing cash collateral. | 1210805.000000000000 |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 28 |
| a. Name of issuer (if any). | Emergent BioSolutions Inc |
| b. LEI (if any) of issuer. (1) | 549300YW6TUOX8BE5103 |
| c. Title of the issue or description of the investment. | Emergent BioSolutions Inc |
| d. CUSIP (if any). | 29089Q105 |
| At least one of the following other identifiers: |
| - ISIN | US29089Q1058 |
| - Ticker (if ISIN is not available). | EBS |
| Balance. (2) |
| a. Balance | 16647.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 172462.920000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.9114205334 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 29 |
| a. Name of issuer (if any). | Enanta Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | 529900SSN4DODDQSN594 |
| c. Title of the issue or description of the investment. | Enanta Pharmaceuticals Inc |
| d. CUSIP (if any). | 29251M106 |
| At least one of the following other identifiers: |
| - ISIN | US29251M1062 |
| - Ticker (if ISIN is not available). | ENTA |
| Balance. (2) |
| a. Balance | 7080.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 286315.200000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.5130994668 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 30 |
| a. Name of issuer (if any). | First American Government Obli |
| b. LEI (if any) of issuer. (1) | 549300R5MYM6VZF1RM44 |
| c. Title of the issue or description of the investment. | First American Government Obligations Fund |
| d. CUSIP (if any). | 31846V336 |
| At least one of the following other identifiers: |
| - ISIN | US31846V3362 |
| - Ticker (if ISIN is not available). | FGXXX |
| Balance. (2) |
| a. Balance | 49722.380000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 49722.380000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.2627695165 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle)
|
| b. Issuer type. (7) |
Registered fund
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 31 |
| a. Name of issuer (if any). | Fulgent Genetics Inc |
| b. LEI (if any) of issuer. (1) | 549300CL6P01M68QJ404 |
| c. Title of the issue or description of the investment. | Fulgent Genetics Inc |
| d. CUSIP (if any). | 359664109 |
| At least one of the following other identifiers: |
| - ISIN | US3596641098 |
| - Ticker (if ISIN is not available). | FLGT |
| Balance. (2) |
| a. Balance | 9208.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 287473.760000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.5192221474 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 32 |
| a. Name of issuer (if any). | Gilead Sciences Inc |
| b. LEI (if any) of issuer. (1) | 549300WTZWR07K8MNV44 |
| c. Title of the issue or description of the investment. | Gilead Sciences Inc |
| d. CUSIP (if any). | 375558103 |
| At least one of the following other identifiers: |
| - ISIN | US3755581036 |
| - Ticker (if ISIN is not available). | GILD |
| Balance. (2) |
| a. Balance | 1734.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 143869.980000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7603144717 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 33 |
| a. Name of issuer (if any). | GSK PLC |
| b. LEI (if any) of issuer. (1) | 5493000HZTVUYLO1D793 |
| c. Title of the issue or description of the investment. | GSK PLC |
| d. CUSIP (if any). | 37733W204 |
| At least one of the following other identifiers: |
| - ISIN | US37733W2044 |
| - Ticker (if ISIN is not available). | GSK |
| Balance. (2) |
| a. Balance | 3992.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 142035.360000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7506189943 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 34 |
| a. Name of issuer (if any). | GreenLight Biosciences Holding |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | GreenLight Biosciences Holdings PBC |
| d. CUSIP (if any). | 39536G105 |
| At least one of the following other identifiers: |
| - ISIN | US39536G1058 |
| - Ticker (if ISIN is not available). | GRNA |
| Balance. (2) |
| a. Balance | 51545.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 22288.060000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.1177864525 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 35 |
| a. Name of issuer (if any). | Gritstone bio Inc |
| b. LEI (if any) of issuer. (1) | 5493003TER6KY3MUVY84 |
| c. Title of the issue or description of the investment. | Gritstone bio Inc |
| d. CUSIP (if any). | 39868T105 |
| At least one of the following other identifiers: |
| - ISIN | US39868T1051 |
| - Ticker (if ISIN is not available). | GRTS |
| Balance. (2) |
| a. Balance | 27912.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 77595.360000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.4100707816 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 36 |
| a. Name of issuer (if any). | HilleVax Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | HilleVax Inc |
| d. CUSIP (if any). | 43157M102 |
| At least one of the following other identifiers: |
| - ISIN | US43157M1027 |
| - Ticker (if ISIN is not available). | HLVX |
| Balance. (2) |
| a. Balance | 10857.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 179466.210000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.9484310531 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 105792.000000000000 |
| Schedule of Portfolio Investments Record: 37 |
| a. Name of issuer (if any). | Hologic Inc |
| b. LEI (if any) of issuer. (1) | 549300DYP6F5ZJL0LB74 |
| c. Title of the issue or description of the investment. | Hologic Inc |
| d. CUSIP (if any). | 436440101 |
| At least one of the following other identifiers: |
| - ISIN | US4364401012 |
| - Ticker (if ISIN is not available). | HOLX |
| Balance. (2) |
| a. Balance | 1724.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 139126.800000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7352480305 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 38 |
| a. Name of issuer (if any). | I-Mab |
| b. LEI (if any) of issuer. (1) | 549300L1A5T19703RR64 |
| c. Title of the issue or description of the investment. | I-Mab |
| d. CUSIP (if any). | 44975P103 |
| At least one of the following other identifiers: |
| - ISIN | US44975P1030 |
| - Ticker (if ISIN is not available). | IMAB |
| Balance. (2) |
| a. Balance | 27396.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 94790.160000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.5009407134 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
CHINA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 58820.000000000000 |
| Schedule of Portfolio Investments Record: 39 |
| a. Name of issuer (if any). | Icosavax Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Icosavax Inc |
| d. CUSIP (if any). | 45114M109 |
| At least one of the following other identifiers: |
| - ISIN | US45114M1099 |
| - Ticker (if ISIN is not available). | ICVX |
| Balance. (2) |
| a. Balance | 12961.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 75173.800000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.3972734829 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 40 |
| a. Name of issuer (if any). | ImmunityBio Inc |
| b. LEI (if any) of issuer. (1) | 529900J9XLBR4HFL4B83 |
| c. Title of the issue or description of the investment. | ImmunityBio Inc |
| d. CUSIP (if any). | 45256X103 |
| At least one of the following other identifiers: |
| - ISIN | US45256X1037 |
| - Ticker (if ISIN is not available). | IBRX |
| Balance. (2) |
| a. Balance | 163948.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 298385.360000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.5768870431 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 289418.220000000000 |
| Schedule of Portfolio Investments Record: 41 |
| a. Name of issuer (if any). | Immunocore Holdings PLC |
| b. LEI (if any) of issuer. (1) | 213800IUE3DFS84BVN18 |
| c. Title of the issue or description of the investment. | Immunocore Holdings PLC |
| d. CUSIP (if any). | 45258D105 |
| At least one of the following other identifiers: |
| - ISIN | US45258D1054 |
| - Ticker (if ISIN is not available). | IMCR |
| Balance. (2) |
| a. Balance | 14822.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 732799.680000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 3.8726508586 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 42 |
| a. Name of issuer (if any). | Inovio Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | 529900B9W875XDZXTM97 |
| c. Title of the issue or description of the investment. | Inovio Pharmaceuticals Inc |
| d. CUSIP (if any). | 45773H201 |
| At least one of the following other identifiers: |
| - ISIN | US45773H2013 |
| - Ticker (if ISIN is not available). | INO |
| Balance. (2) |
| a. Balance | 86366.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 70820.120000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.3742654453 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 43 |
| a. Name of issuer (if any). | Johnson & Johnson |
| b. LEI (if any) of issuer. (1) | 549300G0CFPGEF6X2043 |
| c. Title of the issue or description of the investment. | Johnson & Johnson |
| d. CUSIP (if any). | 478160104 |
| At least one of the following other identifiers: |
| - ISIN | US4781601046 |
| - Ticker (if ISIN is not available). | JNJ |
| Balance. (2) |
| a. Balance | 905.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 140275.000000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7413159613 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 64635.000000000000 |
| Schedule of Portfolio Investments Record: 44 |
| a. Name of issuer (if any). | Laboratory Corp of America Hol |
| b. LEI (if any) of issuer. (1) | OZ7UA8IXAIFILY2VZH07 |
| c. Title of the issue or description of the investment. | Laboratory Corp of America Holdings |
| d. CUSIP (if any). | 50540R409 |
| At least one of the following other identifiers: |
| - ISIN | US50540R4092 |
| - Ticker (if ISIN is not available). | LH |
| Balance. (2) |
| a. Balance | 4842.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 1110851.640000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 5.8705546342 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 45 |
| a. Name of issuer (if any). | Eli Lilly & Co |
| b. LEI (if any) of issuer. (1) | FRDRIPF3EKNDJ2CQJL29 |
| c. Title of the issue or description of the investment. | Eli Lilly & Co |
| d. CUSIP (if any). | 532457108 |
| At least one of the following other identifiers: |
| - ISIN | US5324571083 |
| - Ticker (if ISIN is not available). | LLY |
| Balance. (2) |
| a. Balance | 438.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 150417.960000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7949187996 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 46 |
| a. Name of issuer (if any). | Merck & Co Inc |
| b. LEI (if any) of issuer. (1) | 4YV9Y5M8S0BRK1RP0397 |
| c. Title of the issue or description of the investment. | Merck & Co Inc |
| d. CUSIP (if any). | 58933Y105 |
| At least one of the following other identifiers: |
| - ISIN | US58933Y1055 |
| - Ticker (if ISIN is not available). | MRK |
| Balance. (2) |
| a. Balance | 1290.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 137243.100000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7252931784 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 47 |
| a. Name of issuer (if any). | Moderna Inc |
| b. LEI (if any) of issuer. (1) | 549300EI6OKH5K5Q2G38 |
| c. Title of the issue or description of the investment. | Moderna Inc |
| d. CUSIP (if any). | 60770K107 |
| At least one of the following other identifiers: |
| - ISIN | US60770K1079 |
| - Ticker (if ISIN is not available). | MRNA |
| Balance. (2) |
| a. Balance | 8410.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 1291607.800000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 6.8258027291 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 202725.600000000000 |
| Schedule of Portfolio Investments Record: 48 |
| a. Name of issuer (if any). | Novavax Inc |
| b. LEI (if any) of issuer. (1) | 529900J4GJHPEPQ23205 |
| c. Title of the issue or description of the investment. | Novavax Inc |
| d. CUSIP (if any). | 670002401 |
| At least one of the following other identifiers: |
| - ISIN | US6700024010 |
| - Ticker (if ISIN is not available). | NVAX |
| Balance. (2) |
| a. Balance | 28610.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 198267.300000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.0477897992 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 192314.430000000000 |
| Schedule of Portfolio Investments Record: 49 |
| a. Name of issuer (if any). | Ocugen Inc |
| b. LEI (if any) of issuer. (1) | 549300JVNUI9CXWJLR09 |
| c. Title of the issue or description of the investment. | Ocugen Inc |
| d. CUSIP (if any). | 67577C105 |
| At least one of the following other identifiers: |
| - ISIN | US67577C1053 |
| - Ticker (if ISIN is not available). | OCGN |
| Balance. (2) |
| a. Balance | 73601.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 62789.010000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.3318231709 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 50 |
| a. Name of issuer (if any). | OPKO Health Inc |
| b. LEI (if any) of issuer. (1) | 529900A4S2D4OGOJLL02 |
| c. Title of the issue or description of the investment. | OPKO Health Inc |
| d. CUSIP (if any). | 68375N103 |
| At least one of the following other identifiers: |
| - ISIN | US68375N1037 |
| - Ticker (if ISIN is not available). | OPK |
| Balance. (2) |
| a. Balance | 256528.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 374530.880000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.9792958070 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 51 |
| a. Name of issuer (if any). | OraSure Technologies Inc |
| b. LEI (if any) of issuer. (1) | 529900GNNJPNM4XHXQ77 |
| c. Title of the issue or description of the investment. | OraSure Technologies Inc |
| d. CUSIP (if any). | 68554V108 |
| At least one of the following other identifiers: |
| - ISIN | US68554V1089 |
| - Ticker (if ISIN is not available). | OSUR |
| Balance. (2) |
| a. Balance | 22951.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 138853.550000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7338039771 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 52 |
| a. Name of issuer (if any). | Paratek Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | 5493007V5QDIWECEYV79 |
| c. Title of the issue or description of the investment. | Paratek Pharmaceuticals Inc |
| d. CUSIP (if any). | 699374302 |
| At least one of the following other identifiers: |
| - ISIN | US6993743029 |
| - Ticker (if ISIN is not available). | PRTK |
| Balance. (2) |
| a. Balance | 18339.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 46581.060000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.2461684781 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 53 |
| a. Name of issuer (if any). | Pfizer Inc |
| b. LEI (if any) of issuer. (1) | 765LHXWGK1KXCLTFYQ30 |
| c. Title of the issue or description of the investment. | Pfizer Inc |
| d. CUSIP (if any). | 717081103 |
| At least one of the following other identifiers: |
| - ISIN | US7170811035 |
| - Ticker (if ISIN is not available). | PFE |
| Balance. (2) |
| a. Balance | 3398.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 138638.400000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7326669668 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 54 |
| a. Name of issuer (if any). | Quest Diagnostics Inc |
| b. LEI (if any) of issuer. (1) | 8MCWUBXQ0WE04KMXBX50 |
| c. Title of the issue or description of the investment. | Quest Diagnostics Inc |
| d. CUSIP (if any). | 74834L100 |
| At least one of the following other identifiers: |
| - ISIN | US74834L1008 |
| - Ticker (if ISIN is not available). | DGX |
| Balance. (2) |
| a. Balance | 8299.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 1174142.520000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 6.2050300543 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 1138914.000000000000 |
| Schedule of Portfolio Investments Record: 55 |
| a. Name of issuer (if any). | Regeneron Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | 549300RCBFWIRX3HYQ56 |
| c. Title of the issue or description of the investment. | Regeneron Pharmaceuticals Inc |
| d. CUSIP (if any). | 75886F107 |
| At least one of the following other identifiers: |
| - ISIN | US75886F1075 |
| - Ticker (if ISIN is not available). | REGN |
| Balance. (2) |
| a. Balance | 179.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 147078.930000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7772729166 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 142148.910000000000 |
| Schedule of Portfolio Investments Record: 56 |
| a. Name of issuer (if any). | Sanofi |
| b. LEI (if any) of issuer. (1) | 549300E9PC51EN656011 |
| c. Title of the issue or description of the investment. | Sanofi |
| d. CUSIP (if any). | 80105N105 |
| At least one of the following other identifiers: |
| - ISIN | US80105N1054 |
| - Ticker (if ISIN is not available). | SNY |
| Balance. (2) |
| a. Balance | 2898.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 157709.160000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.8334508469 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
FRANCE
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 82555.140000000000 |
| Schedule of Portfolio Investments Record: 57 |
| a. Name of issuer (if any). | Scilex Holding Co |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Scilex Holding Co |
| d. CUSIP (if any). | 80880W106 |
| At least one of the following other identifiers: |
| - ISIN | US80880W1062 |
| - Ticker (if ISIN is not available). | SCLX |
| Balance. (2) |
| a. Balance | 16589.580100000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 136034.560000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7189063669 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 58 |
| a. Name of issuer (if any). | SIGA Technologies Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | SIGA Technologies Inc |
| d. CUSIP (if any). | 826917106 |
| At least one of the following other identifiers: |
| - ISIN | US8269171067 |
| - Ticker (if ISIN is not available). | SIGA |
| Balance. (2) |
| a. Balance | 23952.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 137724.000000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7278346066 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 58489.000000000000 |
| Schedule of Portfolio Investments Record: 59 |
| a. Name of issuer (if any). | ARS Pharmaceuticals Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | ARS Pharmaceuticals Inc |
| d. CUSIP (if any). | 82835W108 |
| At least one of the following other identifiers: |
| - ISIN | US82835W1080 |
| - Ticker (if ISIN is not available). | SPRY |
| Balance. (2) |
| a. Balance | 31789.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 206946.390000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 1.0936564750 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 60 |
| a. Name of issuer (if any). | Takeda Pharmaceutical Co Ltd |
| b. LEI (if any) of issuer. (1) | 549300ZLMVP4X0OGR454 |
| c. Title of the issue or description of the investment. | Takeda Pharmaceutical Co Ltd |
| d. CUSIP (if any). | 874060205 |
| At least one of the following other identifiers: |
| - ISIN | US8740602052 |
| - Ticker (if ISIN is not available). | TAK |
| Balance. (2) |
| a. Balance | 9004.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 148385.920000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.7841800101 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
JAPAN
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 61 |
| a. Name of issuer (if any). | VBI Vaccines Inc |
| b. LEI (if any) of issuer. (1) | 52990076U5YRLVGDJE40 |
| c. Title of the issue or description of the investment. | VBI Vaccines Inc |
| d. CUSIP (if any). | 91822J103 |
| At least one of the following other identifiers: |
| - ISIN | CA91822J1030 |
| - Ticker (if ISIN is not available). | VBIV |
| Balance. (2) |
| a. Balance | 85744.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 25980.430000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.1372996431 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 62 |
| a. Name of issuer (if any). | Vaxart Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Vaxart Inc |
| d. CUSIP (if any). | 92243A200 |
| At least one of the following other identifiers: |
| - ISIN | US92243A2006 |
| - Ticker (if ISIN is not available). | VXRT |
| Balance. (2) |
| a. Balance | 39005.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 29515.080000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.1559793256 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 63 |
| a. Name of issuer (if any). | Vaxcyte Inc |
| b. LEI (if any) of issuer. (1) | 254900M7NMHTGASX8D95 |
| c. Title of the issue or description of the investment. | Vaxcyte Inc |
| d. CUSIP (if any). | 92243G108 |
| At least one of the following other identifiers: |
| - ISIN | US92243G1085 |
| - Ticker (if ISIN is not available). | PCVX |
| Balance. (2) |
| a. Balance | 18630.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 698252.400000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 3.6900776981 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 64 |
| a. Name of issuer (if any). | Vaxxinity Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Vaxxinity Inc |
| d. CUSIP (if any). | 92244V104 |
| At least one of the following other identifiers: |
| - ISIN | US92244V1044 |
| - Ticker (if ISIN is not available). | VAXX |
| Balance. (2) |
| a. Balance | 43836.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 99507.720000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 0.5258717598 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 65 |
| a. Name of issuer (if any). | Vir Biotechnology Inc |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Vir Biotechnology Inc |
| d. CUSIP (if any). | 92764N102 |
| At least one of the following other identifiers: |
| - ISIN | US92764N1028 |
| - Ticker (if ISIN is not available). | VIR |
| Balance. (2) |
| a. Balance | 34187.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 795531.490000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 4.2041717428 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 66 |
| a. Name of issuer (if any). | Zai Lab Ltd |
| b. LEI (if any) of issuer. (1) | 549300P2UYQ9U5LY1T58 |
| c. Title of the issue or description of the investment. | Zai Lab Ltd |
| d. CUSIP (if any). | 98887Q104 |
| At least one of the following other identifiers: |
| - ISIN | US98887Q1040 |
| - Ticker (if ISIN is not available). | ZLAB |
| Balance. (2) |
| a. Balance | 20931.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 696165.060000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 3.6790466629 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
CHINA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 619301.200000000000 |
| Schedule of Portfolio Investments Record: 67 |
| a. Name of issuer (if any). | Mount Vernon Liquid Assets Portfolio, LLC |
| b. LEI (if any) of issuer. (1) | N/A |
| c. Title of the issue or description of the investment. | Mount Vernon Liquid Assets Portfolio, LLC |
| d. CUSIP (if any). | N/A |
| At least one of the following other identifiers: |
| - Other unique identifier (if ticker and ISIN are not available). Indicate the type of identifier used | 990VR1110 |
| Description of other unique identifier. | USER DEFINED |
| Balance. (2) |
| a. Balance | 4714057.530000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 4714057.530000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 24.9125367261 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Short-term investment vehicle (e.g., money market fund, liquidity pool, or other cash management vehicle)
|
| b. Issuer type. (7) |
Private fund
|
| a. ISO country code. (8) |
UNITED STATES OF AMERICA
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the investment representing cash collateral. | 4714057.530000000000 |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☐ Yes ☒ No |
| Schedule of Portfolio Investments Record: 68 |
| a. Name of issuer (if any). | CureVac NV |
| b. LEI (if any) of issuer. (1) | 724500BUT8GAG9LMYN56 |
| c. Title of the issue or description of the investment. | CureVac NV |
| d. CUSIP (if any). | N/A |
| At least one of the following other identifiers: |
| - ISIN | NL0015436031 |
| - Ticker (if ISIN is not available). | CVAC |
| Balance. (2) |
| a. Balance | 76144.000000000000 |
| b. Units |
Number of shares
|
| c. Description of other units. | |
| d. Currency. (3) |
United States Dollar
|
| e. Value. (4) | 530723.680000000000 |
| f. Exchange rate. | |
| g. Percentage value compared to net assets of the Fund. | 2.8047330957 |
| a. Payoff profile. (5) | ☒ Long ☐ Short ☐ N/A |
| a. Asset type. (6) |
Equity-common
|
| b. Issuer type. (7) |
Corporate
|
| a. ISO country code. (8) |
GERMANY
|
| b. Investment ISO country code. (9) |
| a. Is the investment a Restricted Security? | ☐ Yes ☒ No |
| a. Liquidity classification information. (10) |
| Category. |
N/A
|
| a. Level within the fair value hierarchy (12) | ☒ 1 ☐ 2 ☐ 3 ☐ N/A |
| N/A |
| N/A |
| N/A |
| a. Does any amount of this investment represent reinvestment of cash collateral received for loaned securities? | ☐ Yes ☒ No |
| b. Does any portion of this investment represent that is treated as a Fund asset and received for loaned securities? | ☐ Yes ☒ No |
| c. Is any portion of this investment on loan by the Fund? | ☒ Yes ☐ No |
| i. If Yes, provide the value of the securities on loan. | 514386.000000000000 |
| The Fund may provide any information it believes would be helpful in understanding the information reported in response to any Item of this Form. The Fund may also explain any assumptions that it made in responding to any Item of this Form. To the extent responses relate to a particular Item, provide the Item number(s), as applicable. |
| The Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. |
| Registrant: | ETF Managers Trust |
| By (Signature): | /s/ John Flanagan |
| Name: | John Flanagan |
| Title: | Chief Financial Officer |
| Date: | 2023-04-25 |
1 Year Amplify Junior Silver Mi... Chart |
1 Month Amplify Junior Silver Mi... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
